UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients

Journal of hepatology, 2006-01, Vol.44 (1), p.88-96

2006

Volltextzugriff (PDF)

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)

Journal of clinical oncology, 1999-07, Vol.17 (7), p.2227-2236

1999

Volltextzugriff (PDF)

Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS11-33-PS11-33

2021

Volltextzugriff (PDF)

A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer

Clinical cancer research, 2003-01, Vol.9 (1), p.115-123

2003

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer

Clinical cancer research, 2002-04, Vol.8 (4), p.1042-1048

2002

Volltextzugriff (PDF)

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha

The Journal of pharmacology and experimental therapeutics, 2002-12, Vol.303 (3), p.1334-1343

2002

Volltextzugriff (PDF)

Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer

Clinical cancer research, 2001-05, Vol.7 (5), p.1214-1220

2001

Volltextzugriff (PDF)

Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment

Antiviral therapy, 2004-12, Vol.9 (6), p.953-968

2004

Volltextzugriff (PDF)

A phase I evaluation of multitargeted antifolate (MTA, Ly231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

Cancer chemotherapy and pharmacology, 1999, Vol.44 (5), p.372-380

1999

Volltextzugriff (PDF)

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas

Neuro-oncology (Charlottesville, Va.), 2005-01, Vol.7 (1), p.32-40

2005

Volltextzugriff (PDF)

c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A)

Clinical cancer research, 1999-12, Vol.5 (12), p.3977-3982

1999

Volltextzugriff (PDF)

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer

Investigational new drugs, 2005-10, Vol.23 (5), p.467-477

2005

Volltextzugriff (PDF)

Potential Role of Tamoxifen in Prevention of Breast Cancer

JNCI : Journal of the National Cancer Institute, 1991-10, Vol.83 (20), p.1450-1459

1991

Volltextzugriff (PDF)

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

The New England journal of medicine, 1989-08, Vol.321 (7), p.419-424

1989

Volltextzugriff (PDF)

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Journal of clinical oncology, 2023-12, Vol.41 (36), p.5482-5492

2023

Volltextzugriff (PDF)

Clinical studies of antisense oligonucleotides for cancer therapy

Methods in molecular medicine, 2005, Vol.106, p.85

2005

Volltextzugriff (PDF)

A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer

Clinical colorectal cancer, 2004-11, Vol.4 (4), p.268-274

2004

Volltextzugriff (PDF)

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413

1997

Volltextzugriff (PDF)

Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT006-CT006

2023

Volltextzugriff (PDF)

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

Journal of clinical oncology, 1997-11, Vol.15 (11), p.3394-3398

1997

Volltextzugriff (PDF)

Antisense Approaches for the Treatment of Cancer

Cancer investigation, 2000, Vol.18 (7), p.635-650

2000

Volltextzugriff (PDF)

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-[alpha] administered as a 24-hour weekly infusion schedule in patients with advanced cancer

Investigational new drugs, 2005-10, Vol.23 (5), p.467

2005

Volltextzugriff (PDF)

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-α delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas1, 2

Neuro-oncology (Charlottesville, Va.), 2005-01, Vol.7 (1), p.32-40

2005

Volltextzugriff (PDF)

Presence of an estrogen-regulated protein in endometrial cancer

Obstetrics and gynecology (New York. 1953), 1985-09, Vol.66 (3), p.423

1985

Volltextzugriff (PDF)

Prognostic factors observed in current clinical trials

Cancer, 1993-03, Vol.71 (S6), p.2163-2168

Dorr, F. Andrew

1993

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(68)

Sprache

Englisch
(68)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)

Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients

A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer

Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha

Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer

Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment

A phase I evaluation of multitargeted antifolate (MTA, Ly231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas

c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A)

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer

Potential Role of Tamoxifen in Prevention of Breast Cancer

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Clinical studies of antisense oligonucleotides for cancer therapy

A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

Antisense Approaches for the Treatment of Cancer

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-[alpha] administered as a 24-hour weekly infusion schedule in patients with advanced cancer

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-α delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas1, 2

Presence of an estrogen-regulated protein in endometrial cancer

Prognostic factors observed in current clinical trials

Suchergebnisse filtern